AdCure clinical program
AdCure Bio's clinical development program is focused on developing new viruses that can efficiently reach disseminated cancer cells via intravascular virus delivery.
Currently, our main focus is on lung cancer, the deadliest cancer type in the US, Europe, and Asia. The American Cancer Society estimates that in the US in 2019, there will be 205,335 new cases and 128,403 deaths due to the non-small cell lung cancer, the most prevalent lung cancer type.
AdCure Bio's lead products: AVID-212 and AVID-388
The key technology platform of AdCure Bio is based on oncolytic adenovirus, a common cold virus, engineered to selectively infect and kill tumor cells and stimulate the patient's immune system to eliminate cancer cells from the body.
AdCure Bio’s one-of-a-kind Artificial Vectors for Intravascular Delivery - AVID platform - is ideal for simple intravascular administration because of its safety and unique property of escaping liver sequestration. These features make it suitable for the treatment of cancer patients with disseminated metastatic disease and non-resectable tumors, for whom no effective therapy is currently available.
Based on the available variants of individual AVID capsid proteins, a panel of immunologically distinct oncolytic AVID variants can be assembled for repeated rounds of therapy to improve anti-tumor efficacy and extend survival again and again.
AdCure BIo's pipeline
Using its versatile AVID platform allowing for a safe intravenous virus delivery, AdCure Bio continues to innovate and develop novel oncolytic adenovirus therapeutics to further increase virus potency resistance to pre-existing immunity, and stimulation of patient's own immune system to attack and eliminate cancer cells.
Intellectual property
AdCure Bio owns unrestricted rights to its core therapeutic virus technology
U.S. Patent 9,982,276
Title: "Penton-mutated, integrin-retargeted adenovirus vectors with reduced toxicity and their use".
Issue date: May 29, 2018. Priority date: March, 12, 2015
This patent covers configuration of adenoviruses with modified penton for safe therapeutic gene delivery after intravenous virus administration.
U.S. Patent 10,376,549
Title: "Detargeted Adenovirus Variants and Related Methods".
Priority date: January, 20th, 2015
This U.S patent and international patent applications cover adenovirus configurations suitable for intravenous administration and de-targeted from the liver.
U.S. Continuation Patent Application Serial No. 16/460,160
U.S. Continuation Patent Application Serial No. 16/460,160 entitled: “Detargeted Adenovirus Variants and Related Methods” was filed on November 25, 2019. This continuation patent application is based on our granted US patent 10,376,549 and it expands and defines the methods and therapeutic uses of adenovirus variants, protected under our granted parental U.S patent.
adcure team
Henry Wyche
Dmitry M. Shayakhmetov, PhD
Dmitry M. Shayakhmetov, PhD
Chief Executive Officer
Dmitry M. Shayakhmetov, PhD
Dmitry M. Shayakhmetov, PhD
Dmitry M. Shayakhmetov, PhD
Co-Founder, Senior Vice-President,
Chief Scientific Officer
Nelson C. Di Paolo, PhD
Nelson C. Di Paolo, PhD
Nelson C. Di Paolo, PhD
Co-Founder, Vice-President,
Director of Toxicology and Preclinical Development
Angel A. Rivera, PhD
Nelson C. Di Paolo, PhD
Nelson C. Di Paolo, PhD
Chief Technology Officer
AdCure bio's partners
Intellectual Property Law
Intellectual Property Law
Intellectual Property Law
Our intellectual property partner
Corporate Law
Intellectual Property Law
Intellectual Property Law
Our corporate law partner
Preclinical studies
Intellectual Property Law
Preclinical studies
Research services agreement-based proof-of-concept and mechanism of action tests of AdCure Bio's oncolytic viruses are conducted in state-of-the-art laboratories of Emory University